-
Older Patients with Lenalidomide-Refractory MM May Face Treatment Gaps
10 Mar 2025 22:58 GMT
… appropriate treatment options.
Data from the trial revealed … MS, associate professor of Medicine, Division of Hematology … Ninlaro, 8%), and thalidomide (Thalomid, 1%). Furthermore, the mean … most common drugs used during index treatment included daratumumab …
-
Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies
08 Mar 2025 00:28 GMT
… birth defects caused by thalidomide (Thalomid). Additionally, for patients with del … inducers, treatment with dasatinib is not recommended due to drug level increases … , for oral use. Prescribing information. FDA, 2013. Accessed March 6, 2025 …
-
Elders With Lenalidomide-Refractory Myeloma May Lack Optimal Treatments
04 Mar 2025 18:57 GMT
… Leukemia.
Data from the trial revealed that the median … MS, associate professor of Medicine, Division of Hematology at … (Ninlaro, 8%), and thalidomide (Thalomid, 1%). Furthermore, the mean … The most common drugs used during index treatment included daratumumab …
-
Navigating Pharmaceutical Patent Settlements and Reverse Payments: Key Takeaways from the FTC’s Latest MMA Reports
23 Jan 2025 21:41 GMT
… on pharmaceutical patent settlement agreements filed under the Medicare Prescription Drug, Improvement … 23 agreements involving eight different drug products included quantity restrictions. … ); In re Revlimid & Thalomid Purchaser Antitrust Litig., 2024 U …
-
Myelofibrosis Treatment Options: A Guide for Pharmacists
02 Jan 2025 17:32 GMT
… thalidomide (Thalomid; Bristol Myers Squibb), and other medications. Treatment for the … enlarged spleen may include targeted drug therapies … contribute significantly to optimizing treatment outcomes.
Perhaps most importantly …
-
QOL a Crucial Consideration During R/R Myeloma Treatment Decision-Making
12 Nov 2024 22:41 GMT
… patients and their doctors to work together during treatment decision-making.
… frontline treatment.
Then, we have three different immunomodulating agents: [Thalomid (thalidomide … need pain medication, whether it’s worth continuing treatment, if they …
-
Analyzing Ide-cel’s Trade-offs of Efficacy and Toxicity in Myeloma
26 Mar 2025 03:24 GMT
… Professor
Department of Internal Medicine
Rush University
Chicago, IL … regimens, including an immunomodulatory drug [IMiD], a proteasome inhibitor … very few with thalidomide [Thalomid]. Most people don… Americans included in these trials. So that' …
-
Dr Corre on the Clinical Implications of D-VTd Treatment in Newly Diagnosed Myeloma
18 Oct 2024 23:11 GMT
… Darzalex) plus bortezomib (Velcade), thalidomide (Thalomid), and dexamethasone (D-VTd) in … may benefit from intensified treatment. Additionally, the trial highlights the value … phase 3 MIDAS trial (NCT04934475), which adjusts treatment with another quadruplet …
-
Dr Corre on the Rationale for the CASSIOPEIA Trial in Newly Diagnosed Myeloma
17 Oct 2024 21:05 GMT
… CASSIOPEIA trial (NCT02541383) of daratumumab (Darzalex) plus bortezomib (Velcade), thalidomide (Thalomid), … disease (MRD) negativity following treatment with induction and consolidation D … The trial has established D-VTd as a standard treatment for newly …
-
To Reduce Drug Prices, Issue Fewer Weak Patents
22 Jun 2024 22:13 GMT
… abetting monopoly power in the pharmaceutical industry. I describe numerous examples … ” to ensure that its myeloma drug Thalomid wasn’t used in pregnant … birth defects), Celgene patented the FDA-mandated strategy, rendering it impossible …